Triple Therapy For Patients With Mutated FLT3 Gene In Acute Myeloid Leukemia Oncology Times - OncTimes Talk podcast

Artwork

Medicine Oncology Cancer Oncology Times Science News Health and Well-Being

Indhold leveret af Oncology Times. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Oncology Times eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

Oncology Times - OncTimes Talk « »
Triple Therapy for Patients With Mutated FLT3 Gene in Acute Myeloid Leukemia

2M ago 20:15

Del

Indhold leveret af Oncology Times. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Oncology Times eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

An early study of patients (Phase I/II) with acute myeloid leukemia found that a new three-drug combination therapy greatly improved outcomes—both in patients with relapsed or refractory disease and as initial therapy.

The new research involved adding quizartinib that targets fms-related tyrosine kinase 3 (FLT3) oncogene. Mutations of FLT3 are present in nearly a third of all AML tumors. The internal tandem duplication mutation of FLT3, in particular, is associated with poor prognosis in AML. So, it was hypothesized that targeting FLT3 could help in treating FLT3-mutated AML.

First author Musa Yilmaz MD, Associate Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center, has been talking with OncTimesTalk correspondent Peter Goodwin.

… continue reading

139 episoder

#Medicine #Oncology #Cancer #Oncology Times #Science #News #Health and Well-Being

Artwork

Triple Therapy for Patients With Mutated FLT3 Gene in Acute Myeloid Leukemia

Oncology Times - OncTimes Talk

21 subscribers

published 2M ago

Del

Indhold leveret af Oncology Times. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Oncology Times eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

An early study of patients (Phase I/II) with acute myeloid leukemia found that a new three-drug combination therapy greatly improved outcomes—both in patients with relapsed or refractory disease and as initial therapy.

The new research involved adding quizartinib that targets fms-related tyrosine kinase 3 (FLT3) oncogene. Mutations of FLT3 are present in nearly a third of all AML tumors. The internal tandem duplication mutation of FLT3, in particular, is associated with poor prognosis in AML. So, it was hypothesized that targeting FLT3 could help in treating FLT3-mutated AML.

First author Musa Yilmaz MD, Associate Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center, has been talking with OncTimesTalk correspondent Peter Goodwin.

… continue reading

139 episoder

#Medicine #Oncology #Cancer #Oncology Times #Science #News #Health and Well-Being

All episodes

×

Velkommen til Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

Lyt til 500+ emner